# Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum Disorder

> **NCT07738952** · PHASE1,PHASE2 · RECRUITING · sponsor: **Kyushu University** · enrollment: 7 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder Attack

## Interventions

- **DRUG:** Sivelestat sodium hydrate

## Key facts

- **NCT ID:** NCT07738952
- **Lead sponsor:** Kyushu University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2026-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738952, "Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum Disorder". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07738952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*